Hemolytic uremic syndrome following Campath-1H induction

Hugo Bonatti; Gerald Brandacher; Claudia Boesmueller; Micol Cont; Paul Hengster; Alexander R Rosenkranz; Jens Krugmann; Raimund Margreiter

doi:10.1111/j.1432-2277.2006.00445.x

Hemolytic uremic syndrome following Campath-1H induction

Transpl Int. 2007 Apr;20(4):386-9. doi: 10.1111/j.1432-2277.2006.00445.x.

Authors

Hugo Bonatti¹, Gerald Brandacher, Claudia Boesmueller, Micol Cont, Paul Hengster, Alexander R Rosenkranz, Jens Krugmann, Raimund Margreiter

Affiliation

¹ Department of General and Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.

PMID: 17326780
DOI: 10.1111/j.1432-2277.2006.00445.x

Abstract

Hemolytic uremic syndrome (HUS) is a rare complication following solid organ transplantation. We report on a patient who underwent renal transplantation using Campath-1H induction and tacrolimus maintenance therapy who developed HUS, which was managed by plasma exchange and switch to Rapamycin. However, graft function could not be restored.

Publication types

Case Reports

MeSH terms

Adult
Alemtuzumab
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / adverse effects*
Hemolytic-Uremic Syndrome / chemically induced*
Hemolytic-Uremic Syndrome / drug therapy
Humans
Immunosuppressive Agents / adverse effects*
Kidney Transplantation / adverse effects*
Male
Plasma Exchange
Sirolimus / therapeutic use
Tacrolimus / therapeutic use

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Immunosuppressive Agents
Alemtuzumab
Sirolimus
Tacrolimus